Circulating Tumor Material in Colorectal Cancer and Melanoma

Colorectal Cancer and Melanoma Clinical Trial

Official title:

Protocol to Permit the Acquisition of Circulating Tumor Material in Colorectal Cancer and Melanoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02907086
• Other study ID #: UPCC 12916
• Status: Completed
• Start date: July 7, 2017
• Est. completion date: July 1, 2020

Study information

• Verified date: June 2022
• Source: Abramson Cancer Center of the University of Pennsylvania
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Observational study to allow the collection of blood and medical information to evaluate the role of circulating tumor material in patients with colorectal cancer and melanoma

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7
• Est. completion date: July 1, 2020
• Est. primary completion date: July 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• The subject must be a patient at the Hospital of the University of Pennsylvania

1. Patients with presumed stage II, III, or IV colorectal cancer with planned surgical resection of either the primary tumor or metastatic lesion(s) being evaluated at the Hospital of the University of Pennsylvania

2. Patients with histologically confirmed melanoma stage IIb, IIc, IIIa, IIIb, or IIIc/IV scheduled for surgical resection being evaluated at the Hospital of the University of Pennsylvania.

• The subject must be able to provide informed consent or have an acceptable surrogate capable of giving consent on the subject's behalf.

• The subject must be 18 years of age or older.

Exclusion Criteria:

• The subject is not able to provide informed consent.

Related Conditions & MeSH terms

• Colorectal Cancer and Melanoma
• Colorectal Neoplasms
• Melanoma

Intervention

Other:
• blood collection
Patients will receive a research draw for circulating tumor material analysis with standard clinical labs

Locations

Country	Name	City	State
United States	Abramson Cancer Center of the University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Abramson Cancer Center of the University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of blood samples collected		24 months